Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alaunos Therapeutics (TCRT) Non-Current Deffered Revenue (2016 - 2018)

Historic Non-Current Deffered Revenue for Alaunos Therapeutics (TCRT) over the last 8 years, with Q4 2018 value amounting to $4000.0.

  • Alaunos Therapeutics' Non-Current Deffered Revenue fell 9998.86% to $4000.0 in Q4 2018 from the same period last year, while for Dec 2018 it was $4000.0, marking a year-over-year decrease of 9998.86%. This contributed to the annual value of $4000.0 for FY2018, which is 9998.86% down from last year.
  • Per Alaunos Therapeutics' latest filing, its Non-Current Deffered Revenue stood at $4000.0 for Q4 2018, which was down 9998.86% from $30000.0 recorded in Q3 2018.
  • Alaunos Therapeutics' 5-year Non-Current Deffered Revenue high stood at $49.5 million for Q3 2015, and its period low was $4000.0 during Q4 2018.
  • Its 5-year average for Non-Current Deffered Revenue is $26.4 million, with a median of $37.5 million in 2017.
  • In the last 5 years, Alaunos Therapeutics' Non-Current Deffered Revenue skyrocketed by 553729.41% in 2015 and then tumbled by 9998.86% in 2018.
  • Alaunos Therapeutics' Non-Current Deffered Revenue (Quarter) stood at $850000.0 in 2014, then surged by 5537.29% to $47.9 million in 2015, then fell by 13.33% to $41.5 million in 2016, then dropped by 15.38% to $35.1 million in 2017, then crashed by 99.99% to $4000.0 in 2018.
  • Its last three reported values are $4000.0 in Q4 2018, $30000.0 for Q3 2018, and $49.5 million during Q2 2018.